In this issue:
D(T)PACE chemotherapy still has a role in the treatment of extramedullary RRMM
CPCs detection may be a prognostic biomarker for patients with ND disease
Optimal response to carfilzomib-based therapy achieved regardless of cytogenetics
TMAs after triplet high-dose carfilzomib-based regimen in the front-line setting
Tandem ASCT with sequential use of TMI and high-dose melphalan
Venetoclax regimens elicit deep and durable responses in relapsed t(11;14) disease
Daratumumab-based regimens for NDMM confer a clinical benefit regardless of frailty status
Superior outcomes with maintenance therapy after second ASCT
Bispecific BCMA/CD38 CAR-T cell therapy induces deep and durable remission in RRMM
Budesonide prophylaxis reduces the risk of post-ASCT engraftment syndrome
Please login below to download this issue (PDF)